| scholarly article | Q13442814 |
| P50 | author | Isabella Sperduti | Q37383620 |
| Giuseppe Tonini | Q37838300 | ||
| Luca Moscetti | Q57022939 | ||
| P2093 | author name string | Stefano De Santis | |
| Alessandra Felici | |||
| Fabrizio Nelli | |||
| Massimo Rinaldi | |||
| Giovanni Mansueto | |||
| Giuliana D'Auria | |||
| Francesco C Pollera | |||
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases | Q30881871 | ||
| Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project | Q33330488 | ||
| Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. | Q33345025 | ||
| Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. | Q33345489 | ||
| Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). | Q33348137 | ||
| Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial | Q33349736 | ||
| Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study | Q33365077 | ||
| Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer | Q33503382 | ||
| Chemotherapy for brain metastases of lung cancer: a review | Q33724545 | ||
| Mechanisms of disease: the blood-brain barrier | Q35610735 | ||
| American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. | Q35613883 | ||
| Whole-brain radiotherapy in the management of brain metastasis | Q36416756 | ||
| Chemotherapy of cerebral metastases from solid tumors. | Q41124100 | ||
| First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. | Q44003032 | ||
| Treatment of advanced non-small-cell lung cancer with two-drug combinations | Q44119188 | ||
| Treatment of brain metastases of lung cancer with high doses of etoposide (VP16–213). Cooperative study from the groupe français pneumo-cancérologie | Q48115113 | ||
| Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? | Q48405089 | ||
| The treatment of brain metastases from lung cancer | Q48408193 | ||
| Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide | Q48982725 | ||
| Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis | Q70211565 | ||
| Management of brain metastases | Q72299687 | ||
| Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer | Q73236346 | ||
| Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol | Q73615747 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| brain metastasis | Q1620196 | ||
| P304 | page(s) | 274-281 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology | |
| P478 | volume | 109 |
| Q34387448 | A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer |
| Q48401073 | A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer |
| Q35665643 | Alectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer |
| Q24568071 | Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies |
| Q48569495 | Brain metastases from non-small-cell lung cancer: is there room for improvement? |
| Q34552757 | Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center |
| Q37391069 | Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients |
| Q40670339 | Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions. |
| Q38068204 | EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer |
| Q38763111 | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future |
| Q37682746 | Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? |
| Q36851190 | Gliadel for brain metastasis. |
| Q89449724 | Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer |
| Q52559905 | Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease. |
| Q37738771 | Modern multidisciplinary management of brain metastases |
| Q48695471 | Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors |
| Q42690383 | Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs |
| Q38771929 | Special topics in immunotherapy and radiation therapy: reirradiation and palliation |
| Q38985340 | State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer |
| Q91734009 | Stereotactic Laser Ablation as Treatment of Brain Metastases Recurring after Stereotactic Radiosurgery: A Systematic Literature Review |
| Q38233179 | The diagnosis and treatment of brain metastases in EGFR mutant lung cancer. |
| Q36244603 | The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases |
| Q33599111 | The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline |
| Q38168919 | The role of systemic and targeted therapies in brain metastases |
| Q38197618 | Therapeutic strategy for non-small-cell lung cancer patients with brain metastases (Review). |
Search more.